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Abstract
Background/Aims: Accelerated atherosclerosis in chronic kidney disease (CKD) is preceded 
by endothelial dysfunction (ED), which exhibits a proinflammatory and prothrombotic 
phenotype and enhanced oxidative stress. In this study, the effect of several compounds with 
anti-inflammatory and/or antioxidant properties on uremia-induced endothelial dysfunction 
has been evaluated in an in vitro model. Methods: Endothelial cells (ECs) were exposed to sera 
from uremic patients in the absence and presence of the flavonoids apigenin, genistein and 
quercetin, the antioxidant enzyme mimetics (AEM) ebselen (glutathione peroxidase mimetic), 
EUK-134 and EUK-118 (both superoxide dismutase mimetics), and the pharmacological drug 
N-acetylcysteine (NAC). We explored changes in the expression of adhesion receptors on 
the cell surface, by immunofluorescence, the production of radical oxygen species (ROS), by 
fluorescence detection, and the activation of signaling proteins related to inflammation, by 
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both a phosphospecific antibody cell-based ELISA and immunoblotting techniques. Results: 
Uremic media induced a significantly increased expression of ICAM-1, overproduction of radical 
oxygen species (ROS) and activation of p38 mitogen activated protein kinase (p38MAPK) and 
Nuclear Factor kB (NFkB) in ECs. Quercetin, the AEM and NAC showed a significant inhibitory 
effect on both ICAM-1 expression and ROS generation (p<0.05). All the compounds reduced 
p38MAPK activation, but only the AEM, especially ebselen, and NAC, both potentiating the 
glutathione peroxidase pathway, also inhibited NFkB activation. These two compounds 
were capable of increasing endothelial glutathione levels, especially in response to uremia. 
Conclusion: Our results indicate that the potentiation of the antioxidant pathways can be 
an effective strategy to improve endothelial dysfunction in uremia and a potential target to 
reduce the cardiovascular risk in this population.
Introduction
Endothelial dysfunction (ED) is considered to be the first step in the development and 
progression of atherosclerosis and has been observed in many disorders associated with 
increased cardiovascular morbidity and mortality [1–3]. Chronic kidney disease (CKD), is a 
well-recognized example of a chronic multisystemic disorder associated with an enhanced 
cardiovascular risk [4]. There is clinical [5, 6] and experimental evidence of an inflammatory 
state and enhanced oxidative stress in CKD, both major contributors to the progression of 
cardiovascular disease (CVD) in uremia [7, 8].
Oxidative stress has been proposed to play a major role in the development of ED 
through the production of radical oxygen species (ROS), which activate intracellular signaling 
pathways, including protein kinases, such as mitogen-activated protein kinases (MAPK) [9]. 
Moreover, the uremic endothelium exhibits a proinflammatory phenotype, with an increased 
expression of adhesion molecules and production of proinflammatory cytokines, which have 
been reported as key processes in endothelial activation and damage [10, 11].
Using an in vitro model, our group has previously characterized the CKD-induced 
endothelial damage [12, 13]. Exposure of endothelial cells (ECs) to growth media containing 
sera from uremic patients results in morphological alterations, increased proliferation, 
enhanced thrombogenicity of the extracellular matrix, and increased expression of diverse 
proteins related to inflammation, such as high mobility group box-1 protein (HMGB1), and 
to oxidative stress, such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) 
[14]. Moreover, in recent studies we have demonstrated that these changes are associated 
with enhanced ROS production, the activation of signaling pathways related to cell stress and 
inflammation, such as the p38MAPK and the transcription factor nuclear factor-kB (NFkB) 
[15], as well as to enhanced innate immunity, as seen with toll-like receptor 4 (TLR4) and the 
NALP3 inflammasome [16].
On the other hand, lipid-lowering therapy with statins or the use of renin-angiotensin 
system inhibitors (such as ACE inhibitors or angiotensin receptor blockers) that have proven 
its efficacy in reducing CVD in the general population, as well as subsets of high cardiovascular 
risk patients, such as diabetics or coronary artery disease patients, have failed to prove a 
benefit in dialysis patients [17–19]. Thus, there is a need for alternative therapies able to 
reduce the cardiovascular complications in this population. Strategies that improve ED in 
advanced CKD or ESRD may be a promising therapeutic approach.
Polyphenolic compounds, found in fruits and vegetables, have demonstrated both anti-
inflammatory and antioxidant properties [20]. Different studies assert that a diet rich in 
flavonoids is associated with a reduction in the cardiovascular risk, suggesting that these 
compounds might have potential protective effects on the endothelium [21]. There is evidence 
indicating that mammalian cells activate intrinsic antioxidant defense mechanisms, such as 
antioxidant enzymes, in response to stress molecules induced by ROS production. Recently, 
synthetic compounds with antioxidant enzyme mimetic activity have emerged as novel anti-
inflammatory and antioxidant agents potentially useful in different clinical situations such 
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as stroke, respiratory infections and diabetes [22–24]. A recent systematic review [25] of 
clinical trials, assessing the effects of antioxidant therapy in CKD patients, indicates that 
N-acetylcysteine (NAC) has promising effects by decreasing the levels of oxidative stress 
markers and in a small study it reduced the risk of cardiovascular events in dialysis patients 
[26]. Furthermore, NAC improves endothelial dysfunction in dialysis patients [27] and in an 
in vitro model of uremic dysfunction [28].
The aim of the present study was to investigate the potential protective effect on 
CKD-induced ED of three flavonoids (apigenin, genistein and quercetin), three chemically-
synthesized compounds with antioxidant enzyme mimetic effect (EUK134, EUK118, and 
ebselen), and NAC. We have performed the experiments in our well-characterized in vitro 
model of uremia-induced endothelial dysfunction.
Materials and Methods
Experimental design
Endothelial cells (ECs) were exposed to sera samples from uremic patients under peritoneal dialysis 
(U, n=16) or from healthy donors selected as controls (C, n=15), in the absence and presence of the following 
pharmacological compounds: the flavonoids apigenin (flavone), genistein (isoflavone) and quercetin 
(flavonol); the antioxidant enzyme mimetics ebselen (GPx mimetic), EUK134 and EUK118 (SOD mimetics); 
and NAC, which acts as a donor of cysteine precursors, the substrate for GPx, aimed at glutathione (GSH) 
restoration [29–32]. Cell viability studies (using the MTT assay) were performed to determine the 
appropriate compound concentrations. Cells were pretreated with the compounds for 24h before and during 
the exposure to the growth media containing the uremic serum, to evaluate changes in: i) the expression of 
the cell surface adhesion molecule ICAM-1, ii) the intracellular production of ROS, and iii) the activation of 
the signal transduction protein p38MAPK and NFkB, by ELISA and Western-Blot techniques.
Patients and sample collection
End-stage renal disease patients on peritoneal dialysis using biocompatible solutions with low levels 
of glucose degradation products (GDP) were included. In order to dissect as much as possible uremia from 
other conditions known to induce endothelial dysfunction, diabetic patients, patients with dyslipidemia and/
or previous cardiovascular disease, current smokers and patients who had had an episode of peritonitis in 
the previous 2 months were excluded. Patients’ characteristics are detailed in Table 1. Sex and age-matched 
healthy donors, with no previous history of cardiovascular disease, and preserved renal function (eGFR > 90 
ml/min/1.73 m2, CKD-EPI formula) were enrolled as controls. Written informed consent was obtained from 
every healthy donor and patient included in the study. The study was approved by the Ethics Committee of 
the Hospital Clinic and was carried out according to the principles of the Declaration of Helsinki.
Sera samples were 
obtained from each 
uremic patient and from 
each healthy donor by 
centrifugation of non-
anticoagulated blood 
(3000xg, 15 min) and 
immediately stored at 
-80ºC until used. Pools 
of serum were prepared 
containing serum samples 
from different donors / 
patients, which were used 
as reagent for the different 
experiments performed.
Table 1. Main demographic characteristics, biochemical parameters and 
treatments in healthy subjects (control) and CKD patients 
Parameter Control (15) Uremic (16) 
Age, years (mean ± SD) 57.6 ± 10.0 62.7 ± 20.4 
Gender (male/female) 7/8 7/9 
Residual renal function (ml/min) (mean ± SD) -- 6.4 ± 4.7 
Mean time on dialysis, months (mean ± SD) -- 17.6 ± 8,2 
Serum Albumin (g/dl) (mean ± SD) 4.3 ± 0.3 4.1 ± 0.6 
Hemoglobin (g/dl) (mean ± SD) 12.5 ± 2 11.8 ± 1.9 
Leukocytes (109/L) (mean ± SD) 7.8 ± 1.4 8.1 ± 2.3 
Causes of CKD n (%) 
Glomerulonephritis 
Interstitial nephropathy 
Polycystic kidney disease 











Hypertension, n (%) 0 9 (56.25%) 
Statin prescription, n (%) 0 12 (75%) 
Vitamin D supplementation, n (%) 0 16 (100%) 
Erythropoiesis stimulating agents, n (%) 0 14 (87.5%) 
Inhibitors of the Renin-Angiotensin System,  n (%) 0 9 (56.25%) 
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Materials and reagents
Culture media MEM199, L-glutamine, penicillin/streptomycin, fetal bovine serum (FBS) and accutase 
were all purchased from Gibco-Life Technologies (NY, US). The 3-(4, 5-Dimethylthiazol-2-yl)-2, 5 Diphe-
nyltetrazolium Bromide (MTT) and the flavonoids apigenin, genistein and quercetin were obtained from 
Sigma Aldrich (St.Louis, MO, US). The enzyme mimetics ebselen, EUK134 and EUK118 were purchased from 
Cayman Chemical (MI, US). N-acetylcysteine solution (100 mg/mL) was from Zambon (Barcelona, Spain). 
The pharmacological compounds were dissolved according with manufacturer protocols, with a final con-
centration of DMSO <0.1%, NaOH < 0.01% and EtOH 100% <0.02% in culture medium.
The ROS detection reagent 5-(and 6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate acetyl 
ester (CM-H2DCFDA) was purchased from Molecular Probes (NY, USA). ELISA p38MAPK and NFκB p65 
kit superArrays were obtained from SABiosciences (MD, USA). Antibodies against phospho-p38 MAPK 
(thr180/tyr182), phospho-IκBα (Ser35) and β-actin were from Cell Signaling Technology Inc (MA, US), whi-
le the antibody against ICAM-1 was purchased from Millipore (Temecula, CA, US). Sulfosalicylic acid was 
from Sigma-Aldrich (MO, US) and the commercially available GSH detection kit K0006-F1 was from Arbor 
Assays (MI, US).
Endothelial cell cultures
ECs were isolated from human umbilical veins [32] and maintained in Medium 199 supplemented with 
100 U/mL penicillin,100 g/mL streptomycin and 20% pooled human serum at 37ºC under a humidified 
atmosphere with 5% of CO2. Culture medium was replaced every 48h, together with the compounds under 
study when required. Cells were used between the 2nd and 3rd passage.
Cell viability analysis (MTT assay)
ECs were seeded in a 96-well microplate (10.000 cells/well) and exposed to different concentrations 
of the selected compounds, as well as to the different vehicles used at maximal concentration (0.1% DMSO, 
0.01% NaOH and 0.02% EtOH). After incubation, cell viability was examined by using 3-(4, 5-dimethylthi-
azol- 2-yl)-2, 5-diphenyl-tetrazolium bromide (thiazolyl blue tetrazolium bromide). All procedures were 
performed in triplicate according to the manufacturer’s instructions. The absorbance was measured at 530 
nm. According to the results obtained, experiments were performed using the pharmacological compounds 
under study at the concentrations that exhibited the lowest cell toxicity (less than 10% of cell death), being: 
25 μM apigenin, 0.1 μM genistein, 1 μM quercetin, 5 μM ebselen, 1 μM EUK134, and 5 μM EUK118. NAC was 
used at a concentration of 10 mM, similar to the one used in previous studies [33].
Expression of ICAM-1 on endothelial cell surface
ECs on 6-well microplates were pretreated with the different compounds for 24 h and then stimulated 
with media containing 20% of pooled sera from the uremic patients or healthy donors (24h), according 
to previous studies by our group [15, 34]. Cells were fixed with 2% (for 10 min) followed by 4 % (for 10 
min) paraformaldehyde in 0.15M PBS, pH 7.4 (4°C), blocked with 1% BSA and incubated with a primary 
antibody against ICAM-1 (dilution 1:200, 1 h, RT), and a secondary antibody anti-mouse IgG conjugated 
with Alexa 555 (dilution 1:2000 1 h, at RT) [15]. Then samples were evaluated by light microscopy (Leica 
DM4000B, Barcelona, Spain), images captured through a videocamera (Leica DFC310FX, Barcelona, Spain) 
and the density of labeling calculated by computerized morphometric analysis (ImageJ, National Institutes 
of Health, Bethesda, Maryland, USA). All procedures were performed in duplicate.
Production of intracellular reactive oxygen species (ROS)
ROS production was explored by using the ROS detection reagent CM-H2DCFDA. This compound can 
passively diffuse into cells and it is specifically oxidized into the highly fluorescent dichlorofluorescein 
(DCF) by ROS. The measure of the fluorescence emitted reflects the intracellular ROS production.
ECs seeded on 24-well plates (TPP, Sigma-Aldrich, MO, US) were preincubated with 10 µM CM-H2DCF-
DA (37ºC, 15 min). Then, cells were washed with PBS (3x) followed by cell stimulation with pooled uremic 
serum for 30 min in the absence and presence of the compounds under study. Intracellular ROS production 
was monitored by fluorescence microscopy (Leica DM4000B, Barcelona, Spain), images captured through 
a videocamera (Leica DFC310FX, Barcelona, Spain) and the density of labeling calculated by computerized 
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morphometric analysis (ImageJ, National Institutes of Health, Bethesda, Maryland, USA). All procedures 
were performed in duplicate [15].
Activation of p38MAPK and NFκB signaling pathways in endothelial cells
To investigate the effect of the different compounds studied on the activation of the inflammation-re-
lated signaling pathways p38MAPK and NFКB, we performed two different approaches: a phosphospecific 
antibody cell-based ELISA and immunoblotting techniques.
In order to carry out the phosphospecific antibody cell-based ELISA, ECs were seeded in 96-well plates 
and pretreated with the different flavonoids and mimetics for 24 h. After 4 h of starving (media with 2% 
pooled human sera), ECs were then incubated for 15 min with the uremic sera in the absence or presence of 
the selected compounds. Detection of total and phosphorylated protein expression was determined by colo-
rimetric quantification of the relative amount of phosphorylated protein and total target protein, according 
to the manufacturer‘s protocol, and results were corrected for cell number [14].
Immunoblotting techniques were then performed to confirm the results obtained by ELISA. In this 
case, ECs seeded on 6-well plates were pretreated, after starving for 4 h, with the different compounds (24 
h), followed by incubation with uremic sera for 15 min [13, 15]. Cells were lysed with Laemmli buffer (125 
mmol/l of Tris-HCl, 2% SDS, 5% glycerol, and 0.003% bromophenol blue), sonicated for 15 sec to shear DNA 
and reduce viscosity, and heated to 90°C for 5 min. Protein concentrations of the supernatants were deter-
mined using the Bradford’s method. Samples were resolved by 10% sodium dodecyl sulphate polyacryla-
mide gel (SDS-PAGE) and proteins were transferred to nitrocellulose membranes. After blocking with 2% 
BSA, membranes were probed with the specific primary antibodies phosphorylated p38MAPK (Thr180 and 
Tyr182), phosphorylated IКBand β-actin, used as loading control. Considering that translocation of NFКB 
to the nucleus is preceded by the phosphorylation and degradation of IКB, we decided to analyze the phos-
phorylation of the IКBprotein in the presence of N-acetyl-leucyl-leucyl-norleucinal (ALLN) which blocks 
IКBdegradation by the 26S proteasome [14]. Following extensive washing, membranes were incubated with 
a peroxidase-conjugated anti-rabbit immunoglobulin G and visualized using the chemiluminiscence tech-
nique. Densitometric analysis was performed to quantify the intensity of phosphorylation (ImageJ, National 
Institutes of Health, Bethesda, Maryland, USA) and results were normalized relative to β-actin.
Evaluation of intracellular GSH
To evaluate intracellular levels of GSH, cells were grown in 6-well plates (TPP, Sigma-Aldrich, MO, US) 
to confluence. Cells were incubated with 20% uremic or control sera and in presence or absence of ebselen 
and/or NAC for 24h. Cells were then washed with PBS and collected with accutase. Cell pellets were depro-
teinized in cold 5% sulfosalicylic acid (SSA, Sigma-Aldrich) and centrifuged (2500xg, 5 min). Sample super-
natants were analyzed using the commercial kit K0006-F1 (Arbor Assays) in a fluorimeter (Fluoroskan FL) 
following the manufacturer’s procedure. Raw data, corrected with respect to the cell number, is expressed 
as a fold increase of GSH with respect to the control.
Statistics
Results are expressed as mean ± standard deviation (SD) of data generated in independent experi-
ments (n) using different cell batches and different pooled serum samples from various patients. Statistical 
analyses were performed by using ANOVA with the SPSS statistical package 17.0.0 (SPSS Inc, Chicago, IL). 
Results were considered statistically significant when p<0.05.
Results
Changes in the expression of ICAM-1 on the endothelial cell surface
There was an enhanced expression of the adhesion molecule ICAM-1 on the cell surface 
in response to the uremic sera (U) when compared to control sera (increase of 111 ± 2% vs 
control, n=5, p<0.01) (Fig. 1). When cells were pretreated with flavonoids, only quercetin 
had a slight but statistically significant effect on ICAM-1 expression (decrease of 26 ± 11% 
with respect to the uremic condition, n=5, p<0.05), whereas no remarkable changes were 
observed when apigenin and genistein were used. In contrast, the antioxidant enzyme mi-
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Fig. 1. Antioxidant enzyme mimetics 
prevent the increase in the expression 
of ICAM-1 on the endothelial cell 
surface induced by uremic sera. 
ECs were pretreated with apigenin 
(25µM), genistein (0.1 µM), quercetin 
(1 µM), ebselen (5 µM), EUK134 (1 
µM) and EUK118 (5 µM) for 24h and 
then stimulated with media containing 
20% different pooled sera from 
uremic patients or healthy donors. 
Surface expression of the surface 
receptor ICAM-1 was explored by 
immunofluorescence. Micrographs 
show the ICAM-1 surface expression 
in ECs exposed to control media (C), 
uremic condition (U) and uremic condition treated with ebselen (U+ebselen). Bar diagrams show the effect 









metics ebselen, EUK134 and EUK118 significantly inhibited the expression of ICAM-1 on the 
ECs surface exposed to uremic sera, with ICAM-1 expression levels similar to those obtained 
in control experiments (decreases of 47 ± 6%, 42 ± 11% and 53 ± 6% vs the uremic conditi-
on, respectively, n=5, p<0.01) (Fig. 1). No changes were observed in control cells after being 
exposed to the different compounds.
Production of intracellular ROS by endothelial cells
The incubation of ECs with uremic sera for 15 min resulted in an increase in the levels of 
ROS of 117 ± 3% compared to control levels (n=5, p<0.01). Pretreatment of cells with ebse-
len and quercetin had a remarkably significant inhibitory effect on intracellular ROS genera-
tion induced by the uremic sera (decreases of 56 ± 5% and 37 ± 4% vs the uremic condition, 
n=5, p<0.01). The inhibitory effect of the antioxidant enzyme mimetics EUK134 and EUK118 
was moderate (decreases of 23 ± 3% and 26 ± 2%, respectively, vs the uremic condition, n=5, 
p<0.05). Genistein induced a significant but less intense reduction (11 ± 3% vs the uremic 
condition, n=5, p<0.05), whereas apigenin did not modify ROS production (Fig. 2). No signi-
ficant changes were observed in control cells in response to the compounds under study.
Modulation of the activation of intracellular protein p38MAPK
The exposure of ECs to the uremic sera for 15 min resulted in a significant activation 
of p38MAPK (increase of 90 ± 5% vs control sera, n=5, p<0.05), this increase in the phos-
phorylation of p38MAPK was inhibited by pretreating ECs with all the pharmacological 
compounds under study. The flavonoid apigenin and ebselen induced a potent inhibition of 
p38MAPK activation (decreases of 37 ± 19% and 49 ± 9% respectively, vs the uremic conditi-
on, n=5, p<0.01). Pretreatment with quercetin, EUK134 and EUK118 produced a remarkable 
but less intense reduction of p38MAPK activation (decreases of 32 ± 16%, 26 ± 14% and 
28 ± 15%, respectively, vs the uremic group, p<0.05). Genistein induced a slight, although 
statistically significant, decrease of the p38MAPK phosphorylation (decrease of 16 ± 6% vs 
uremic condition, p<0.05) (Fig. 3A). Western Blot analysis confirmed the results obtained 
by ELISA (Fig. 3B). No modifications on the activation of p38MAPK were detected in control 
cells exposed to the compounds under study.
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Effect on the NFКB signaling pathway
Activation of NFКB (p65) protein was significantly higher after exposing ECs to the sera 
from the uremic patients when compared to the control experiments (increase of 80± 6% 
with respect to controls, n=4, p<0.01) (Fig. 4A). No differences were observed in the phos-
phorylation levels of NFКB (p65) when ECs were previously treated with the flavonoids as-
sayed. NFКB activation was notably attenuated by ebselen and EUK118 (decreases of 21 ± 
7% and 17 ± 7% vs the uremic condition, respectively, n=4, p<0.05) and the most remarkable 
reduction was observed in the presence of EUK134 (decrease of 31 ± 16% vs uremic con-
dition, n=4, p<0.01). Western Blot analysis of IКBphosphorylation showed similar results 
as those obtained with the cell-based ELISA assay (Fig. 4B). Exposure of control cells to the 
compounds under study did not induce any modification in the IКBphosphorylation.
Fig. 2. ROS production in endothelial 
cells exposed to uremic media is 
inhibited with pharmacological 
approaches. After pretreatement 
with apigenin (25 µM), genistein 
(0.1 µM), quercetin (1 µM), ebselen 
(5 µM), EUK134 (1 µM) and EUK 
118 (5 µM) for 24 h, ECs were 
stained with the cell permeable ROS 
detection reagent H2DFFDA (10μM, 
10min), washed with PBS, and 
exposed to sera from healthy donors 
(C) and uremic patients (U), for 
30min. ROS production was detected 
by fluorescence microscopy. Bar 
diagrams show the effect of the uremic sera (#p<0.05 vs control) and the different compounds assayed 






Fig. 3. Activation of p38MAPK 
signaling pathway by uremic 
sera is inhibited by flavonoids 
and antioxidant mimetics. ECs 
were incubated (15 min) with 
sera from control donors (C), 
and uremic patients (U) in the 
absence and presence of apigenin, 
genistein, quercetin, ebselen, 
EUK134 and EUK118 (n=5). A. Bar 
diagrams represent the ratios of 
phosphorylated p38 MAPK relative 
to the total protein, obtained 
from antibody cell-based ELISA 
technique. B. Phospho-p38 MAPK in 
ECs was also assessed by Western-
Blot. Images are representative of 4 
different experiments. Results were quantified and represented as Mean±SD by bar diagram. # p<0.01 vs 
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Anti-inflammatory and 





ties in ECs exposed to the 
uremic condition, show-
ing effects comparable to 
ebselen regarding inflam-
mation markers and even 
greater with respect to the 
antioxidant effect. NAC was 
able to inhibit the expres-
sion of ICAM-1 (decrease 
of 49 ± 8% vs the uremic 
condition, n=4, p<0.01), in-
tracellular ROS generation 
(decrease of 62 ± 12% vs 
the uremic condition, n=4, 
p<0.01), phosphorylation 
of p38MAPK (decrease of 
47 ± 13% vs the uremic 
condition, n=5, p<0.01), 
and NFКB activation (decrease of 31 ± 8% vs the uremic condition, n=4, p<0.01) (Fig. 5).
Changes of GSH levels in endothelial cells treated with ebselen and NAC
Cells grown under uremic conditions showed slightly higher GSH concentrations than 
control cells (% of increase of 28 ± 17% vs. control, n=5). Ebselen pretreatment increased 
GSH levels in both control and uremic cells (% of increase with respect to their baseline con-
dition of 32 ± 3%, n=5, p<0.01, and of 18 ± 14%, n=5, p<0.05, respectively). NAC also raised 
GSH levels in cell culture in both the control and the uremic conditions (increases of 24 ± 
Fig. 4. Activation of NFκB 
(p65) signaling pathway by 
uremic sera is prevented 
by antioxidant enzyme 
mimetics. ECs were 
incubated (15 min) with 
sera from control donors 
(C), and uremic patients (U) 
in the absence and presence 
of apigenin, genistein, 
quercetin, ebselen, EUK134 
and EUK118 (n=4). A. Ratios 
of phosphorylated NFκB 
(p65) relative to the total 
protein. Data are corrected 
for cell number and are 
represented as Mean±SD. 
B. IκB was assessed by 
Western-Blot in ECs previously treated with ALLN (50 µg/ml, 30 min, 37°C). Images are representative of 4 






Fig. 5. Anti-inflammatory and antioxidant effects of NAC on endothelial 
cells exposed to uremic sera. Micrographs show ICAM-1 surface 
expression and ROS production in ECs exposed to control media (C), 
uremia (U) and uremia treated with NAC (U+NAC). Bar diagrams 
show the effect of the uremic sera (# p<0.05 vs control) and the NAC 
treatment (*p<0.05, **p<0.01 vs uremia) (n=4). NAC (10mM) inhibited 
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3%, n=5, p<0.01 and 32 ± 15%, n=5, p<0.05, re-
spectively). Coincubation with ebselen and NAC 
together in the culture media increased GSH in 
ECs both in control and uremic cells (47 ± 13%, 
n=5, p<0.05 and 52 ± 7%, n=5, p<0.01, respec-
tively) (Fig. 6).
Discussion
In the present study we confirm that endo-
thelial dysfunction in uremia is associated with a 
proinflammatory phenotype and enhanced oxi-
dative stress, as we and others have previously 
demonstrated [13-16, 28, 35-37]. Furthermore, 
we have shown the different protective effects 
of several anti-inflammatory and antioxidant 
strategies. While some of the flavonoids assa-
yed exhibited moderate anti-inflammatory and 
antioxidant effects, the antioxidant enzyme mi-
metics of SOD and GPx, and NAC, were more ef-
fective at inhibiting the expression of adhesion 
molecules on the cell surface, ROS production, 
and the activation of the inflammation-related 
pathways p38MAPK and NFКB. Interestingly, the enhancement of the GPx pathway, either by 
a mimetic of the enzyme activity (ebselen) or by promoting the restoration of the reduced 
glutathione (NAC), proved to be the most effective strategy to protect the endothelium from 
the deleterious effect of the uremic milieu.
An imbalance between oxidative stress and the antioxidant mechanisms, together with 
the chronic inflammation present in uremia, are likely to play a major role in the develop-
ment of an accelerated atherosclerosis and enhanced cardiovascular risk in long-term dialy-
sis patients [4, 6–8]. Therefore, the modulation of inflammation and oxidative stress appears 
to be a promising strategy to prevent endothelial damage in this condition. Based on our 
previous evidence [13, 15, 35, 36], we aimed to investigate the potential protective effect 
of different compounds with antioxidant and/or anti-inflammatory properties on the CKD-
induced endothelial dysfunction.
Flavonoids possess certain antitumoral, antioxidant, and anti-inflammatory activities 
[37, 38]. However, there are several limitations to assay these compounds as potential phar-
macological targets: the large number of the identified flavonoids, their different chemical 
structures and the high doses required, difficult to achieve with a regular diet. In our stu-
dy, only the flavonol quercetin prevented ROS production, being the only flavonoid tested 
able to also reduce the expression of the adhesion receptor ICAM-1, and the activation of 
the inflammation-related pathways p38MAPK and NFКB. Although the isoflavone genistein 
reduced the generation of ROS and the phosphorylation of p38MAPK, it failed to prevent 
NFКB activation and ICAM-1 expression in uremic ECs. The flavone apigenin did not show 
any antioxidant effect on ECs exposed to the conditions assayed. In contrast with our results, 
there are studies reporting beneficial antioxidant and anti-inflammatory effects of genistein 
and apigenin in other situations. These effects include the prevention of LDL oxidation, the 
attenuation of ROS production, the inhibition of NFКB signaling pathway and the expression 
of cell adhesion molecules [39–42]. The discrepancies with the results found in our study 
suggest that the effect of these compounds may depend on several factors, including dosage, 
type of stimuli and the heterogeneity of ECs lines used in the in vitro studies.
Uremic patients exhibit an impaired production of endogenous antioxidant defenses 
and accumulate uremic toxins that induce oxidative stress [43–46]. Moreover, the accumula-
Fig. 6. GSH restoration is promoted by ebselen 
and NAC in endothelial cell cultures. Endothelial 
cell cultures were grown in the presence of 
control or uremic sera for 24h. Bar diagrams 
represent GSH levels with respect to the control. 
The effect of the compounds was statistically 
compared with respect to their respective basal 
situation (# p<0.05 and ## p<0,01 vs control; 
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tion of endogenous ROS results in the activation of intracellular signaling pathways involved 
in proliferation, survival, and inflammatory responses [46]. The main intracellular antioxi-
dant enzymes include SOD and GPx, among others. Recently, a group of cell-permeable and 
low molecular weight antioxidant enzyme mimetics are acquiring growing interest for the 
prevention of complications related to conditions associated with enhanced oxidative stress. 
Of those, EUK118 and EUK134 show SOD enzyme mimetic activity; while ebselen, an or-
ganoselenium compound, catalyzes the reduction of ROS in a manner similar to GPx. This 
last compound also reacts with the thioredoxin system and acts as a dehydroascorbic acid 
reductase mimetic. Our present results clearly demonstrated that the antioxidant enzyme 
mimetics studied exhibit not only free radical scavenging activity, but also anti-inflammatory 
effects, with a significant inhibition of the activation of the signaling pathways p38MAPK and 
NFКB, together with the reduction in the expression of adhesion molecules on the EC surface 
when cells were exposed to the uremic condition.
Interestingly, ebselen and NAC showed the most potent protective antioxidant and anti-
inflammatory effects on ECs exposed to uremic milieu. Ebselen appears to be a promising 
drug because of the multiplicity of its mechanisms for inhibiting free radical-induced injury 
coupled with a rapid absorption following oral administration. However, as ebselen has been 
shown to have significant cellular toxicity, novel ebselen-based agents are being developed 
[47]. NAC is currently used as an antioxidant and a mucolytic agent. The therapeutic potenti-
al of NAC is currently being investigated as an antidote for specific toxins, as a bioprotective 
agent against oxidative stress and ischemic injury, and as a treatment for certain mental and 
physical disorders. Although reduced glutathione is the most important intracellular antio-
xidant, oral administration of NAC is even more efficient than direct glutathione administra-
tion [48]. Further, NAC stimulates glutathione-S-transferase activity, promotes detoxification 
and acts as a scavenger of free radicals due to its direct interaction with ROS [49]. GPx pa-
thway is largely known to minimize lipid peroxidation of cellular membranes and other bio-
logical processes associated with oxidative stress. Thus, the potentiation of this antioxidant 
pathway could be a promising strategy to prevent uremia-induced endothelial dysfunction. 
In fact, a decrease in plasma levels of GSH or GPx have been shown in CKD patients [9, 45-
47], and a decreased GSH/GSSG ratio in ECs exposed to uremic media have been previously 
reported [35]. This later finding is in contrast to our results, since a slight increase in GSH 
in uremic endothelial cells has been observed, which could be a compensatory response 
against the prooxidant state present in endothelial cells in response to the uremic milieu. 
However, and in agreement with the previous and another study, uremic endothelial dys-
function was improved by NAC [28, 35], as well as by ebselen. Furthermore, the combined 
effect of ebselen and NAC on GSH levels were additive in uremic endothelial cells, suggesting 
a beneficial effect of enhancing the GPx pathway in CKD-induced ED.
The main limitations of the present study are that the concentrations used in these 
experiments were based on cell viability analysis and not plasma levels physiologically or 
pharmacologically achieved. The results of this in vitro model should be confirmed in in vivo 
studies.
The results of the present study indicate that uremic endothelial dysfunction can be mi-
nimized through an antioxidant strategy. While the benefit of flavonoids is unclear and may 
be controversial due to the concentrations needed to cause a beneficial effect, the changes 
observed with the antioxidant enzyme mimetics and NAC indicate that these compounds 
may be promising therapeutic strategies to provide endothelial protection against the ure-
mic insult. Specifically, the activation of the glutathione peroxidase pathway, either by using 
an enzyme mimetic and/or by providing the substrate for GSH through NAC, reduce not only 
the oxidative stress but also the inflammatory process induced by the uremic milieu on the 
endothelium.
Basic and clinical investigations provide strong evidence of the development of an en-
dothelial dysfunction in chronic kidney disease (CKD), leading to accelerated atherosclerosis 
and increased cardiovascular risk. However, a pharmacological holistic approach to reduce 
the broad features involved in vascular remodeling in CKD remains to be discovered. The 
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results of our study provide a new approach for the prevention and treatment of the CKD-
related endothelial dysfunction, and perhaps can arise as a useful strategy to reduce the 
incidence of cardiovascular events in this high risk population.
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